Ranbaxy USA Inc., the American subsidiary of Ranbaxy Laboratories Limited, an Indian generic pharmaceutical maker, has agreed to pay $ 500 million to settle
fines related to claims that it made false statements to the FDA about its
manufacturing practices abroad and sold substandard medications and pay penalties.